MDxHealth reports Q4 EPS (14c) vs. (39c) last year

Reports Q4 revenue $24.74M, consensus $22.67M. Reports fourth quarter adjusted EBITDA of ($1.4M) , a 68% improvement over prior year period; Fourth quarter tissue-based, Confirm mdx and GPS,test volume of 11,789, an increase of 50% over prior year period; Fourth quarter liquid-based , Select mdx, Resolve mdx, Germline, test volume of 12,036, an increase of 10% over prior year period;Year-end cash and cash equivalents balance of $46.8M…Michael K. McGarrity, CEO of mdxhealth (MDXH), commented: “We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our performance in Q4 underscores our commitment to deliver sustainable growth and puts us on track to achieve adjusted EBITDA profitability in the first half of this year. We continue to see strong adoption of our expanded menu of tests, and our commercial team is driving further penetration into our key urology market. With the pending draw of the second tranche under our OrbiMed debt facility, our balance sheet will be significantly strengthened to meet our 2025 earnout obligation to Exact Sciences as well as support the execution of our 2025 business plan. We are confident in our ability to deliver continued growth and deliver value to our stakeholders, including patients, customers and shareholders.”